Valuation: Kamada Ltd.

Market Cap 1.52B 0 500M 439M 412M 377M 704M 47.86B 709M 4.95B 1.92B 24.4B 1.88B 1.84B 79.11B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.52B 0 500M 439M 412M 377M 704M 47.86B 709M 4.95B 1.92B 24.4B 1.88B 1.84B 79.11B EV / Sales 2026 *
2.51x
EV / Sales 2027 * 2.25x
Free-Float
54.68%
Yield 2026 *
-
Yield 2027 * -
1 day+1.44%
1 week+6.98%
Current month+8.90%
1 month+4.63%
3 months+25.85%
6 months+3.49%
Current year+18.05%
1 week 2,450
Extreme 2450
2,698
1 month 2,400
Extreme 2400
2,698
Current year 2,013
Extreme 2013
2,890
1 year 1,956
Extreme 1956
2,890
3 years 1,685
Extreme 1685
3,045
5 years 1,309
Extreme 1309
3,045
10 years 1,309
Extreme 1309
4,500
Manager TitleAgeSince
Chief Executive Officer 58 30/06/2015
Director of Finance/CFO 56 30/12/2017
Chief Operating Officer 54 31/10/2016
Director TitleAgeSince
Director/Board Member 75 12/12/1990
Chairman 77 06/03/2013
Chairman 55 11/08/2020
Date Insider Type Main position Quantity % Market Cap. Importance
14/09/26 Exercice

VP Quality

61,323 0.1063%
14/09/26 Sell

Founder

-22,827 0.0396%
14/09/26 Exercice

General Counsel

23,459 0.0407%
Change 5-day change 1-year change 3-year change Capi.($)
+1.44%+6.98%+19.11%+35.98% 504M
-1.61%+2.16%+39.35%-5.19% 80.27B
+1.28%+26.53%+614.46%+87.69% 72.88B
-0.82%+2.86%-10.04%-28.92% 61.51B
-1.80%-3.26%-13.41%+26.38% 47.39B
-0.89%+2.67%+3.52%+165.50% 46.58B
-1.14%+3.18%+59.99%-12.60% 33.3B
-1.99%-0.38%+47.00%+111.53% 25.73B
+0.29%+8.84%+9.19%+176.10% 22.88B
-1.92%+0.05%+57.90%+98.91% 15.82B
Average -0.68%+6.08%+82.71%+65.54% 40.69B
Weighted average by Cap. -0.75%+7.28%+125.83%+52.15%

Financials

2026 *2027 *
Net sales 606M 0 199M 175M 165M 150M 281M 19.11B 283M 1.98B 766M 9.74B 749M 733M 31.58B 673M 0 222M 195M 183M 167M 312M 21.23B 315M 2.2B 851M 10.82B 832M 814M 35.09B
Net income 84.8M 0 27.91M 24.5M 23.03M 21.06M 39.35M 2.67B 39.64M 277M 107M 1.36B 105M 103M 4.42B 104M 0 34.27M 30.08M 28.28M 25.85M 48.31M 3.28B 48.67M 340M 132M 1.67B 129M 126M 5.43B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
462
Date Price Change Volume
23/09/26 ILA 2,668.00 +1.44% 185,065
22/09/26 ILA 2,630.00 -0.11% 131,704
17/09/26 ILA 2,633.00 +5.57% 129,318
16/09/26 ILA 2,494.00 +2.17% 114,135
15/09/26 ILA 2,441.00 -2.55% 101,220
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KMDA Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!